ArticleDiscover oncology2026
PatchSight-ImmuneMap-LifeSpan as a unified AI framework for breast cancer diagnosis, immune profiling and prognostic prediction.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predictive models for intestinal obstruction: from clinical scores to artificial intelligence.Frontiers in surgery · 2026Review
- Fetal health state detection method based on parameters efficient ensembling of deep learning.Frontiers in public health · 2026Article
- Bridging Global Attention and Local Hierarchies: A Robust Hybrid Ensemble Framework With Multi-Perspective Explainability for Automated HER2-IHC Scoring.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer diagnosis, immune cell profile, and survival forecasting are important but usually done separately, limiting clinical interpretation. This work combines histopathological diagnosis, immunological microenvironment analysis, and prognostic modeling into a data-driven pipeline. The proposed system involves three phases: PatchSight Classifier uses an optimized InceptionResNetV2 network with patch-based augmentation and transfer learning to classify benign and malignant breast tissue from the BreakHis dataset; ImmuneMap Detector uses Faster R-CNN on immunohistochemistry images from the LYSTO dataset to detect and quantify tumor-infiltrating lymphocytes; and LifeSpan Prognosticator integrates diagnostic and immune features. The PatchSight Classifier outperformed VGG-16, DenseNet-121, and baseline InceptionResNetV2 models with 98.76% accuracy and 0.98 F1-score at 400× magnification. ResNet-101’s ImmuneMap Detector had 98% detection accuracy and low lymphocyte counting inaccuracy. The LifeSpan Prognosticator identified survival-influencing biomarkers with a C-index above 0.90. This comprehensive computational pathology system improves diagnostic precision, immunological assessment, and survival prediction with interpretable, high-accuracy models. We provide end-to-end decision assistance for early detection, immunological assessment, and personalized breast cancer prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.